Zoledronic acid i.v. 2 years — Competitive Intelligence Brief

Zoledronic acid i.v. 2 years (Zoledronic acid i.v. 2 years) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Oncology, Bone Diseases.

phase 3 Bisphosphonate Hydroxyapatite Oncology, Bone Diseases Small molecule

Target snapshot

Zoledronic acid i.v. 2 years (Zoledronic acid i.v. 2 years) — Ludwig-Maximilians - University of Munich. Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zoledronic acid i.v. 2 years TARGET	Zoledronic acid i.v. 2 years	Ludwig-Maximilians - University of Munich	phase 3	Bisphosphonate	Hydroxyapatite
strontium-89	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake
Effervescent and buffered alendronate	Effervescent and buffered alendronate	Aarhus University Hospital	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Sodium Fluoride Dentifrice	Sodium Fluoride Dentifrice	Procter and Gamble	marketed	Fluoride topical agent	Tooth enamel hydroxyapatite; bacterial enolase
Sodium monofluorophosphate toothpaste	Sodium monofluorophosphate toothpaste	Procter and Gamble	marketed	Fluoride toothpaste	Tooth enamel hydroxyapatite; bacterial enolase
sodium fluoride calcium fluoride	sodium fluoride calcium fluoride	University of Pernambuco	marketed	Fluoride supplement / dental caries preventive	Hydroxyapatite crystal structure; bacterial glycolytic enzymes
Vanish XT Dental Varnish	Vanish XT Dental Varnish	University of Nebraska	marketed	Topical fluoride varnish	Tooth enamel (hydroxyapatite)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

1. · 2 drugs in this class
2. Amgen · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Sanofi · 2 drugs in this class
5. Ludwig-Maximilians - University of Munich · 2 drugs in this class
6. Chinese University of Hong Kong · 1 drug in this class
7. Chinese Society of Lung Cancer · 1 drug in this class
8. Aarhus University Hospital · 1 drug in this class
9. Eisai Inc. · 1 drug in this class
10. Daiichi Sankyo Co., Ltd. · 1 drug in this class